ERBB2 and breast carcinoma: Clinical trials utilizing anti-HER2 agents already approved for use in human breast cancers (such as trastuzumab [14], pertuzumab [15] and lapatinib [16]) so far showed only moderate clinical benefit in persistent or recurrent HER2-positive EOC patients [12].